Literature DB >> 22921884

Scattered dose to radiosensitive organs and associated risk for cancer development from head and neck radiotherapy in pediatric patients.

Kalliopi M Kourinou1, Michalis Mazonakis, Efrosini Lyraraki, John Stratakis, John Damilakis.   

Abstract

The purpose of this study was to measure the scattered dose to out-of-field organs from head and neck radiotherapy in pediatric patients and to estimate the risk for second cancer induction to individual organs. Radiotherapy for thalamic tumor, brain tumor, acute leukemia and Hodgkin's disease in the neck region was simulated on 5 and 10-year-old pediatric phantoms with a 6 MV photon beam. The radiation dose to thyroid, breast, lung, stomach, ovaries, bladder, liver, uterus, prostate and colon was measured using thermoluminescent dosimeters. The methodology, provided by the BEIR VII report was used for the second cancer risk estimations. Peripheral dose range for a simulated 5-year-old patient was 0.019%-1.572% of the given tumor dose. The corresponding range at the advanced patient age was reduced to 0.018%-1.468%. The second cancer risk per fraction for male patients varied from 3 to 215 per 1,000,000 patients depending upon the age at the time of exposure, primary cancer site and organ scattered dose. The corresponding risk for females was 1-1186 per 1,000,000 patients. The higher risk values were found for breast, thyroid and lung cancer development. The current data concerning the risk magnitude for developing subsequent neoplasms to various out-of-field organs may be of value for health care professionals in the follow-up studies of childhood cancer survivors.
Copyright © 2012 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer risk; Organ dose; Pediatric patients; Radiotherapy

Mesh:

Year:  2012        PMID: 22921884     DOI: 10.1016/j.ejmp.2012.08.001

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  6 in total

1.  Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy.

Authors:  Emel Haciislamoglu; Yunus Cinar; Fatih Gurcan; Emine Canyilmaz; Gorkem Gungor; Adnan Yoney
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

2.  The Measurement of Thyroid Absorbed dose by Gafchromic™ EBT2 Film and Changes in Thyroid Hormone Levels Following Radiotherapy in Patients with Breast Cancer.

Authors:  Leyla Ansari; Neda Nasiri; Fahimeh Aminolroayaei; Karim Ghazikhanlou Sani; Masoumeh Dorri-Giv; Razzagh Abedi-Firouzjah; Dariush Sardari
Journal:  J Med Signals Sens       Date:  2020-02-06

3.  Dosimetric and radiobiological comparison of simultaneous integrated boost radiotherapy for early stage right side breast cancer between three techniques: IMRT, hybrid IMRT and hybrid VMAT.

Authors:  Suyan Bi; Rui Zhu; Zhitao Dai
Journal:  Radiat Oncol       Date:  2022-03-28       Impact factor: 3.481

4.  Thyroid function following radiation therapy in breast cancer patients: risk of radiation-induced hypothyroidism.

Authors:  Negin Farshchian; Nasrin Amirifard; Mohammad Hosein Saiedian Azar; Sahel Heydarheydari; Nazanin Farshchian; Abbas Haghparast
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19

5.  Development of clinical application program for radiotherapy induced cancer risk calculation using Monte Carlo engine in volumetric-modulated arc therapy.

Authors:  Dong-Jin Kang; Young-Joo Shin; Seonghoon Jeong; Jae-Yong Jung; Hakjae Lee; Boram Lee
Journal:  Radiat Oncol       Date:  2021-06-12       Impact factor: 3.481

6.  Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.

Authors:  Boram Lee; Sung Hwan Ahn; Hyeyoung Kim; Jaeman Son; Jiwon Sung; Youngyih Han; Seung Jae Huh; Jin Sung Kim; Dong Wook Kim; Myonggeun Yoon
Journal:  J Appl Clin Med Phys       Date:  2016-09-08       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.